NEW YORK (GenomeWeb News) — Shares in Vermillion, formerly Ciphergen Biosystems, were up 9.3 percent, or $.08, at $.94 in mid-afternoon trading today after the company published findings showing how a protein biomarker may help diagnose peripheral artery disease.
Specifically, the findings suggest that the biomarker, called beta-2 microglobulin, is elevated in patients with PAD and that the level of the protein is correlated with the severity of the disease.
The research set to be published in the September issue of the journal Circulation and is currently available online.
PAD affects approximately 10 million people in the US and increases their risk of developing heart and vessel complications. Vermillion said it has penned an alliance with Quest Diagnostics to “expedite development and release” of a PAD test.